At the Medical University of South Carolina, Hongjun Wang, Ph.D., and her team have engineered stem cells that do something insulin injections alone cannot: they reverse new-onset type 1 diabetes in mice by teaching the immune system to stop attacking insulin-producing cells. This work, published in Molecular Therapy, marks a fundamental shift in how researchers think about treating a disease that affects millions globally—not by managing blood sugar, but by addressing the root cause of immune dysfunction itself.
Type 1 diabetes is an autoimmune disease in which the body's own T-cells mistakenly destroy the insulin-producing beta cells in the pancreas. People with T1D require multiple daily insulin injections for life, yet insulin alone cannot halt the immune assault or prevent devastating long-term complications like kidney disease, blindness, and nerve damage. "While insulin injections are lifesaving," Wang explains, "they cannot stop immune attacks, and they do not prevent long-term complications."
The breakthrough begins with mesenchymal stem cells (MSCs)—adult stem cells with a natural talent for healing tissue and regulating immunity. Previous trials showed that standard MSCs could preserve some remaining insulin production, but they weren't strong enough to fully reverse established disease. Wang's team engineered these cells to produce alpha-1 antitrypsin (AAT), a protective protein that shields against inflammation. This genetic modification creates a dual action: the AAT-MSCs simultaneously protect surviving insulin-producing cells and dampen the overactive immune response that would otherwise overwhelm them.
But the real transformation happens at the cellular level. Using single-cell analysis of thousands of immune cells, Wang's team discovered that AAT-MSC therapy doesn't simply suppress the immune system—it reprograms it. The therapy retrains two opposing forces: T-regulatory cells, the peacekeeper immune cells that protect insulin production, and CD8+ killer T-cells, the attackers that drive the assault on beta cells. In type 1 diabetes, the attackers vastly outnumber the peacekeepers, destroying insulin production. After AAT-MSC treatment, Wang observed a striking increase in peacekeeper cells and a dramatic decrease in active attacker cells, which appeared driven to exhaustion.
What sets this treatment apart is its durability. Though the stem cells themselves are cleared from the body within hours or days, the immune reprogramming effect persists. "To impact or cure T1D, the stem cells themselves don't need to be there," Wang notes. The cells work by secreting microscopic factors that continue protecting the body's organs long after the cells vanish—a mechanism that could extend treatment effects for six months to two years, based on clinical experience with MSCs for other diseases.
The research specifically focused on new-onset diabetes, that critical early window when patients still retain insulin-producing cells worth rescuing. Wang's team is now testing the safety and efficacy of this approach in an ongoing clinical trial with new-onset type 1 diabetes patients. For millions living with T1D, this represents something profoundly different: not just better management, but the possibility of genuine reversal through immune system retraining.